Transaction #21555 · Form 4 · 0001214504-25-000007
Celldex Therapeutics, Inc. · Exercise / conversion · Common Stock
Celldex Therapeutics, Inc. · Transacted December 15, 2025 · Filed December 17, 2025
What does this filing report?
An SEC Form 4 filing for Celldex Therapeutics, Inc. records an exercise / conversion involving Common Stock on December 15, 2025. The reported quantity was 8,333. The filing date is December 17, 2025. This is one transaction record; amounts are not allocated among any joint reporting owners.
The acquisition category describes how securities were received. It does not by itself establish a cash purchase of common stock. Read the transaction code definitionsand the original filing before interpreting the amounts.
Transaction details
- Company
- Celldex Therapeutics, Inc.
- Company CIK
- 0000744218
- Security type
- Non-derivative
- Acquisition type
- Exercise / conversion · Code M
- Quantity acquired
- 8,333
- Reported price
- 9.0165 · See footnotes
- Reference value
- 75,134.4945
- Currency
- Currency not specified
- Ownership
- Direct
- Holdings after transaction
- 9,097
- Ownership description
- Not reported
- SEC acceptance time
- Dec 17, 2025, 4:06 PM EST
- 10b5-1 indication
- Not indicated
Reference value is reported quantity × reported price. It is not a confirmed cash payment or an estimate of a derivative's economic value. A missing currency is not assumed to be USD.
Reporting owners
- PEPIN RONALD ↗
SR. VP & CBO
CIK 0001214504
These are the reporting owners named in the filing. Quantities and amounts are not allocated among co-reporters. Roles reflect this filing, not a current profile.
Company listings
The linked listing is identified separately from other current company listings.
Filing footnotes & remarks
- F1
- On February 8, 2019, Celldex Therapeutics, Inc. effected a 1-for-15 reverse stock split of its common stock (the "Reverse Stock Split"). This option was previously reported as covering 200,000 shares at an exercise price of $0.6011 per share, but has been adjusted to reflect the Reverse Stock Split.
- F2
- Includes 764 shares of common stock acquired under the Celldex Therapeutics, Inc. 2004 Employee Stock Purchase Plan.
- F3
- As of June 13, 2022, the option is fully vested.
- F4
- As of June 19, 2023, the option is fully vested.
Footnotes are reproduced as plain text from the current source filing. For the full context, read the original SEC filing.
This record was updated Eastern Time. This is the stored record update time, not the transaction date. Report a correction.